Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast

Daniel W Visscher, F. H. Sarkar, S. Wykes, K. Kothari, J. Macoska, J. Crissman

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Methanol/acetone-fixed frozen sections of 87 breast carcinomas were stained with a panel of three anti-p53 monoclonal antibodies that had specificities for wild-type, mutant, or combined wild-type plus mutant epitopes by using the avidin-biotin method. Nuclear staining was present in 13 (15%) of 87 cases with the mutant-specific antibody. The combined- specificity antibody stained 28 (32%) of 87 cases, including all but one of the tumors that was positive with the mutant-specific antibody. None of the cases reacted with the wild-type-specific antibody. Immunostaining for mutant form p53 was strongly correlated with adverse clinicopathologic factors, including poor differentiation, absence of estrogen receptor protein, nodal metastases, and large tumor size. In groups that were stratified by axillary node status, disease-free survival (52-month mean follow-up) was worse among cases with positive staining for either antibody. This difference was statistically significant in node-positive patients with the combined- specificity antibody (disease free, 22% [p53+] vs recurred, 57% [p53+]). We concluded that (1) immunostaining for mutant forms of p53 characterizes a clinically aggressive subset of breast tumors and may have prognostic utility in some patient populations, and (2) antibody-dependent-staining patterns for p53 may reflect epitope specificities of various mutant forms.

Original languageEnglish (US)
Pages (from-to)973-976
Number of pages4
JournalArchives of Pathology and Laboratory Medicine
Volume117
Issue number10
StatePublished - 1993
Externally publishedYes

Fingerprint

Adenocarcinoma
Breast
Antibody Specificity
Antibodies
Staining and Labeling
Epitopes
Breast Neoplasms
Avidin
Frozen Sections
Biotin
Acetone
Disease-Free Survival
Methanol
Neoplasms
Monoclonal Antibodies
Neoplasm Metastasis
Population

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Visscher, D. W., Sarkar, F. H., Wykes, S., Kothari, K., Macoska, J., & Crissman, J. (1993). Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast. Archives of Pathology and Laboratory Medicine, 117(10), 973-976.

Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast. / Visscher, Daniel W; Sarkar, F. H.; Wykes, S.; Kothari, K.; Macoska, J.; Crissman, J.

In: Archives of Pathology and Laboratory Medicine, Vol. 117, No. 10, 1993, p. 973-976.

Research output: Contribution to journalArticle

Visscher, DW, Sarkar, FH, Wykes, S, Kothari, K, Macoska, J & Crissman, J 1993, 'Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast', Archives of Pathology and Laboratory Medicine, vol. 117, no. 10, pp. 973-976.
Visscher, Daniel W ; Sarkar, F. H. ; Wykes, S. ; Kothari, K. ; Macoska, J. ; Crissman, J. / Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast. In: Archives of Pathology and Laboratory Medicine. 1993 ; Vol. 117, No. 10. pp. 973-976.
@article{f8a5fe3bfbf04cbc8b2d373bf58afad4,
title = "Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast",
abstract = "Methanol/acetone-fixed frozen sections of 87 breast carcinomas were stained with a panel of three anti-p53 monoclonal antibodies that had specificities for wild-type, mutant, or combined wild-type plus mutant epitopes by using the avidin-biotin method. Nuclear staining was present in 13 (15{\%}) of 87 cases with the mutant-specific antibody. The combined- specificity antibody stained 28 (32{\%}) of 87 cases, including all but one of the tumors that was positive with the mutant-specific antibody. None of the cases reacted with the wild-type-specific antibody. Immunostaining for mutant form p53 was strongly correlated with adverse clinicopathologic factors, including poor differentiation, absence of estrogen receptor protein, nodal metastases, and large tumor size. In groups that were stratified by axillary node status, disease-free survival (52-month mean follow-up) was worse among cases with positive staining for either antibody. This difference was statistically significant in node-positive patients with the combined- specificity antibody (disease free, 22{\%} [p53+] vs recurred, 57{\%} [p53+]). We concluded that (1) immunostaining for mutant forms of p53 characterizes a clinically aggressive subset of breast tumors and may have prognostic utility in some patient populations, and (2) antibody-dependent-staining patterns for p53 may reflect epitope specificities of various mutant forms.",
author = "Visscher, {Daniel W} and Sarkar, {F. H.} and S. Wykes and K. Kothari and J. Macoska and J. Crissman",
year = "1993",
language = "English (US)",
volume = "117",
pages = "973--976",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "10",

}

TY - JOUR

T1 - Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast

AU - Visscher, Daniel W

AU - Sarkar, F. H.

AU - Wykes, S.

AU - Kothari, K.

AU - Macoska, J.

AU - Crissman, J.

PY - 1993

Y1 - 1993

N2 - Methanol/acetone-fixed frozen sections of 87 breast carcinomas were stained with a panel of three anti-p53 monoclonal antibodies that had specificities for wild-type, mutant, or combined wild-type plus mutant epitopes by using the avidin-biotin method. Nuclear staining was present in 13 (15%) of 87 cases with the mutant-specific antibody. The combined- specificity antibody stained 28 (32%) of 87 cases, including all but one of the tumors that was positive with the mutant-specific antibody. None of the cases reacted with the wild-type-specific antibody. Immunostaining for mutant form p53 was strongly correlated with adverse clinicopathologic factors, including poor differentiation, absence of estrogen receptor protein, nodal metastases, and large tumor size. In groups that were stratified by axillary node status, disease-free survival (52-month mean follow-up) was worse among cases with positive staining for either antibody. This difference was statistically significant in node-positive patients with the combined- specificity antibody (disease free, 22% [p53+] vs recurred, 57% [p53+]). We concluded that (1) immunostaining for mutant forms of p53 characterizes a clinically aggressive subset of breast tumors and may have prognostic utility in some patient populations, and (2) antibody-dependent-staining patterns for p53 may reflect epitope specificities of various mutant forms.

AB - Methanol/acetone-fixed frozen sections of 87 breast carcinomas were stained with a panel of three anti-p53 monoclonal antibodies that had specificities for wild-type, mutant, or combined wild-type plus mutant epitopes by using the avidin-biotin method. Nuclear staining was present in 13 (15%) of 87 cases with the mutant-specific antibody. The combined- specificity antibody stained 28 (32%) of 87 cases, including all but one of the tumors that was positive with the mutant-specific antibody. None of the cases reacted with the wild-type-specific antibody. Immunostaining for mutant form p53 was strongly correlated with adverse clinicopathologic factors, including poor differentiation, absence of estrogen receptor protein, nodal metastases, and large tumor size. In groups that were stratified by axillary node status, disease-free survival (52-month mean follow-up) was worse among cases with positive staining for either antibody. This difference was statistically significant in node-positive patients with the combined- specificity antibody (disease free, 22% [p53+] vs recurred, 57% [p53+]). We concluded that (1) immunostaining for mutant forms of p53 characterizes a clinically aggressive subset of breast tumors and may have prognostic utility in some patient populations, and (2) antibody-dependent-staining patterns for p53 may reflect epitope specificities of various mutant forms.

UR - http://www.scopus.com/inward/record.url?scp=0027377932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027377932&partnerID=8YFLogxK

M3 - Article

C2 - 8215837

AN - SCOPUS:0027377932

VL - 117

SP - 973

EP - 976

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 10

ER -